Do variants in MTR, SHMT1, MTHFD1, and FOLH1 raise folate requirements and risk higher homocysteine when folate is low-normal?

The efficiency of one-carbon metabolism (OCM) is a critical determinant of cardiovascular and metabolic health, particularly in the management of homocysteine levels. Research confirms that genetic variants in key OCM enzymes—specifically MTR, SHMT1, MTHFD1, and FOLH1—significantly alter how the body processes folate and manages homocysteine, particularly when folate availability is not optimal.

Clinical and metabolic evidence

Genetic polymorphisms in these four genes directly impair the biochemical flux required for homocysteine remethylation:

• MTR (Methionine Synthase): The MTR A2756G variant affects the enzyme responsible for the final step of homocysteine remethylation. Studies show that polymorphisms like rs12749581 modify homocysteine responses specifically when folate intake is low, as the enzyme lacks the necessary efficiency to clear homocysteine without high substrate concentrations.
• FOLH1 (Folate Hydrolase 1): This gene encodes the enzyme responsible for converting dietary folylpolyglutamates into absorbable monoglutamates. Variants reduce intestinal absorption efficiency, lowering systemic folate availability and indirectly increasing homocysteine risk when dietary intake is only marginal.
• MTHFD1 and SHMT1: The MTHFD1 G1958A (rs2236225) variant reduces enzyme activity by up to 30-50%, while SHMT1 C1420T shifts folate flux away from the homocysteine remethylation cycle toward DNA synthesis.

Mechanistic explanations

These variants create a state of "functional folate deficiency" through distinct pathways:

• Substrate Sensitivity: When folate levels are in the "low-normal" range (e.g., lower quartiles of reference ranges), the enzymatic inefficiencies caused by these variants become rate-limiting. This "bottleneck" effect prevents the rapid conversion of homocysteine to methionine.
• Gene-Nutrient Interaction: In models of MTHFD1 and SHMT1 deficiency, metabolic disruptions are often specifically reversible by increasing folate or choline intake. This indicates that the genetic impairment increases the baseline physiological demand for folate; a "normal" level of folate may be insufficient to maintain homeostasis for individuals with these genotypes.
• Network Synergy: Because these enzymes work in a coordinated network, having variants across multiple points (e.g., absorption via FOLH1 and remethylation via MTR) creates a cumulative risk for hyperhomocysteinemia that is highly sensitive to folate status.

Bottom line

Genetic variants in MTR, SHMT1, MTHFD1, and FOLH1 increase the baseline requirement for folate and make individuals significantly more susceptible to elevated homocysteine when folate status is low-normal. For these individuals, maintaining folate levels in the higher end of the reference range is likely necessary to overcome enzymatic inefficiencies.